AstraZeneca Signs Collaboration Agreement with Targacept for New Neuronal Nicotinic Receptor Compounds Phase II compound for improving cognitive deficits in Alzheimer’s Disease and Schizophrenia included in agreement. AstraZeneca today announced that it has signed an exclusive global licensing and research collaboration agreement with Targacept Inc. for the development and commercialization of Targacept's phase II compound, TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders. The four-year research collaboration also allows for the development of other
Data Show Survival Benefit For Arimidex™ In Early Breast Cancer Data presented today at the San Antonio Breast Cancer Symposium (SABCS), Texas has found that 'Arimidex' (anastrozole) is the first aromatase inhibitor (AI) to provide an overall survival benefit, compared with tamoxifen, in the treatment of hormone-sensitive early breast cancer.
Thursday, 8 December 2005
AstraZeneca and Protherics Announce Late Stage Licensing Agreement On CytoFab™ AstraZeneca today announced a global development and commercialisation agreement for Protherics anti-sepsis product CytoFab™. CytoFab™ is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).
SYMBICORT® MAINTENANCE AND RELIEVER THERAPY™ IS HIGHLY EFFECTIVE COMPARED WITH ANY DOSE OF SERETIDE™ 17th November 2005. Lund, Sweden. New clinical trial data, published today in the European Respiratory Journal (ERJ), reveals that AstraZeneca’s novel treatment concept - SYMBICORT® Maintenance And Reliever Therapy™ - is highly effective compared with Seretide™ (fluticasone/ salmeterol). The study also provides further evidence that a treatment regimen using just one inhaler for patients day-to-day needs, maintenance and relief, is at least as effective in a real world setting to multiple inhaler
Tuesday, 15 November 2005
NEW AZD6140 PHASE IIb DATA PRESENTED AT AMERICAN HEART ASSOCIATION Dallas, TXNovember 15, 2005 New Phase IIb data from the DISPERSE2 Study 1 presented today at the American Heart Association Meeting, assessed the safety, tolerability and preliminary efficacy of AstraZeneca’s AZD6140 plus aspirin compared to clopidogrel plus aspirin in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Wednesday, 9 November 2005
AstraZeneca Commences Patent Infringement Litigation Against Teva AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. for willful infringement of AstraZeneca’s substance patent protecting Seroquel.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.